AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Trexquant Investment LP

Trexquant Investment LP decreased its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 38.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,720 shares of the biotechnology company's stock after selling 37,152 shares during the period. Trexquant Investment LP owned about 0.20% of AnaptysBio worth $804,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of ANAB. KLP Kapitalforvaltning AS acquired a new position in AnaptysBio during the 4th quarter worth $40,000. AlphaQuest LLC raised its position in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 4,237 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock valued at $85,000 after buying an additional 644 shares during the period. SG Americas Securities LLC grew its position in shares of AnaptysBio by 35.0% during the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company's stock worth $216,000 after buying an additional 4,231 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of AnaptysBio during the third quarter worth approximately $250,000.

AnaptysBio Trading Up 5.9 %

Shares of NASDAQ ANAB traded up $1.13 during trading hours on Thursday, reaching $20.19. The stock had a trading volume of 173,156 shares, compared to its average volume of 588,535. The firm has a 50-day moving average of $17.48 and a 200-day moving average of $20.26. The firm has a market cap of $619.26 million, a price-to-earnings ratio of -3.32 and a beta of -0.09. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.89. The business had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, equities analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has initiated a stock buyback program on Monday, March 24th that allows the company to buyback $75.00 million in outstanding shares. This buyback authorization allows the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Wolfe Research started coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price for the company. JPMorgan Chase & Co. raised their price target on AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Truist Financial lowered their price objective on AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a research report on Wednesday, December 18th. Finally, Wedbush reissued an "outperform" rating and set a $40.00 target price on shares of AnaptysBio in a research report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $33.63.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.